367 results on '"Huhn, Andrew S."'
Search Results
2. Supervised Withdrawal Opioid Use Disorder Treatments
3. Within-subject, double-blind, randomized, placebo-controlled evaluation of combining the cannabinoid dronabinol and the opioid hydromorphone in adults with chronic pain
4. Age moderates the association of optimism on craving during substance use disorder treatment
5. Substance Use in the Performing Artist with Chronic Pain.
6. A brief measure of non-drug reinforcement: Association with treatment outcomes during initial substance use recovery
7. Methadone maintenance patients lack analgesic response to a cumulative intravenous dose of 32 mg of hydromorphone
8. Patterns of demoralization and anhedonia during early substance use disorder treatment and associations with treatment attrition
9. The impact of opioid-stimulant co-use on tonic and cue-induced craving
10. Supervised Withdrawal Opioid Use Disorder Treatments
11. Sex as a Biological Variable and Gender as a Social Construct in the Treatment of Opioid Use Disorder
12. Latent patterns of sleep disturbance, pain impact, and depressive symptoms in residential substance use treatment
13. Preliminary evidence of different and clinically meaningful opioid withdrawal phenotypes
14. Patterns of polysubstance use and clinical comorbidity among persons seeking substance use treatment: An observational study
15. Within subject, double blind, examination of opioid sensitivity in participant-reported, observed, physiologic, and analgesic outcomes.
16. COVID-19–Related Financial Hardship Is Associated With Depression and Anxiety in Substance Use Treatment Across Gender and Racial Groups
17. The association of chronic pain and opioid withdrawal in men and women with opioid use disorder
18. Individuals with Chronic Pain Who Misuse Prescription Opioids Report Sex-Based Differences in Pain and Opioid Withdrawal.
19. The relationship between pupil diameter and other measures of opioid withdrawal during naloxone precipitated withdrawal
20. Recovery Goals and Long-term Treatment Preference in Persons Who Engage in Nonmedical Opioid Use
21. Prefrontal cortex response to drug cues, craving, and current depressive symptoms are associated with treatment outcomes in methadone-maintained patients
22. Analgesic Effects of Hydromorphone versus Buprenorphine in Buprenorphine-maintained Individuals.
23. A hidden aspect of the U.S. opioid crisis: Rise in first-time treatment admissions for older adults with opioid use disorder
24. Objective sleep outcomes in randomized-controlled trials in persons with substance use disorders: A systematic review
25. Patient-reported sleep outcomes in randomized-controlled trials in persons with substance use disorders: A systematic review
26. To take or not to take: the association between perceived addiction risk, expected analgesic response and likelihood of trying novel pain relievers in self‐identified chronic pain patients
27. The relationship between treatment accessibility and preference amongst out-of-treatment individuals who engage in non-medical prescription opioid use
28. The association of pain impact and sleep disruption with opioid withdrawal during opioid‐use disorder treatment
29. Knowledge, Preference, and Adverse Effects of Xylazine Among Adults in Substance Use Treatment
30. Intersectional Risk and the Significant Gap in Care for Persons with Co-occurring Chronic Pain and Opioid Withdrawal
31. Reregulation of cortisol levels and sleep in patients with prescription opioid use disorder during long-term residential treatment
32. Familial perceptions of appropriate treatment types and goals for a family member who has opioid use disorder
33. A preliminary examination of the multiple dimensions of opioid craving
34. The association of prefrontal cortex response during a natural reward cue-reactivity paradigm, anhedonia, and demoralization in persons maintained on methadone
35. Within-subject, double-blinded, randomized, and placebo-controlled evaluation of the combined effects of the cannabinoid dronabinol and the opioid hydromorphone in a human laboratory pain model
36. Improving Translational Research Outcomes for Opioid Use Disorder Treatments
37. Harm Reduction for Opioid Use Disorder: Strategies and Outcome Metrics.
38. Differences in patient-reported and observer-rated opioid withdrawal symptom etiology, time course, and relationship to clinical outcome
39. Evidence of Buprenorphine-precipitated Withdrawal in Persons Who Use Fentanyl
40. Integration of Patient-reported Outcomes Assessment Into Routine Care for Patients Receiving Residential Treatment for Alcohol and/or Substance Use Disorder
41. Suvorexant alters dynamics of the sleep-EEG power spectrum and depressive symptom trajectories during inpatient opioid withdrawal
42. Polymorphisms in the A118G SNP of the OPRM1 gene produce different experiences of opioids: A human laboratory phenotype–genotype assessment
43. Increased neural activity in the right dorsolateral prefrontal cortex during a risky decision-making task is associated with cocaine use in methadone-maintained patients
44. Craving and opioid use disorder: A scoping review
45. Randomized comparison of two web-based interventions on immediate and 30-day opioid overdose knowledge in three unique risk groups
46. The relationship between pupil diameter and other measures of opioid withdrawal during naloxone precipitated withdrawal
47. A hidden aspect of the U.S. opioid crisis: Rise in first-time treatment admissions for older adults with opioid use disorder
48. Transgender individuals are at higher risk for suicidal ideation and preparation than cisgender individuals in substance use treatment
49. Serious About the Opioid Epidemic? Expand Medicaid
50. Provider Continuity in the Prescribing of Buprenorphine/Naloxone Within Medicare Part D
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.